Inflammatory Cytokine Levels in Patients with Sporadic Amyotrophic Lateral Sclerosis
Inflammatory Cytokine Levels in Patients with Sporadic Amyotrophic Lateral Sclerosis
复制标题
DOI：
10.1159/000522078
复制
发表时间：
2021-01-01
影响因子：
3
通讯作者：
Huang, Xusheng
中科院分区：
文献类型：
--
作者：
Sun, Qionghua;Huo, Yunyun;Huang, Xusheng
目的：在本研究中，对散发性肌萎缩侧索硬化症（sALS）患者外周血中的炎症因子，包括白细胞介素（IL）和肿瘤坏死因子-α（TNF-α）进行了评估，并研究了这些变量是否与疾病的进展和严重程度相关。研究方法：回顾性收集了2018年3月至2021年3月期间中国人民解放军总医院收治的248例sALS患者的炎症因子数据，包括IL- 1、IL-2、IL-6、IL-8、IL-10和TNF-α。分析各变量与临床特征（包括性别、发病年龄、发病部位、发病至入院时间、ALS功能评定量表评分和诊断类别）之间的关系。结果如下：ALS患者IL-1、IL-2、IL-6、IL-8、IL-10和TNF-α水平分别高于正常值范围的43.75%、7.04%、16.42%、25.35%、1.41%和50.72%。IL-2和IL-6水平与ALS功能评定量表评分呈负相关（r =-0.280，p = 0.004和r =-0.198，p = 0.048）。结论：炎性细胞因子水平升高支持ALS中炎症反应的假设，IL-2和IL-6可用作疾病严重程度的炎症相关生物标志物。(c)南纬2022年Karger AG，巴塞尔
Objectives: In the present study, inflammatory factors, including interleukin (IL) and tumor necrosis factor-alpha (TNF-alpha) in the peripheral blood of patients with sporadic amyotrophic lateral sclerosis (sALS), were evaluated, and the issue of whether these variables were associated with the progression and severity of the disease examined. Methods: Data on inflammatory factors, including IL- 1, IL-2, IL-6, IL-8, IL-10, and TNF-alpha, were retrospectively collected from 248 sALS patients admitted to the Chinese PLA General Hospital between March 2018 and March 2021. The relationships between the variables and clinical features, including gender, age at onset, site of onset, time from onset to hospital admission, ALS functional rating scale score, and diagnostic category were analyzed. Results: IL-1, IL-2, IL-6, IL-8, IL-10, and TNF-alpha levels were elevated in 43.75%, 7.04%, 16.42%, 25.35%, 1.41%, and 50.72% of ALS patients, respectively, compared with the normal value range. IL-2 and IL-6 levels were inversely associated with the ALS functional rating scale score (r = -0.280, p = 0.004 and r = -0.198, p = 0.048). Conclusion: Elevated levels of inflammatory cytokines support the hypothesis of an inflammatory response in ALS, and IL-2 and IL-6 may be used as an inflammation-related biomarker for disease severity. (c) 2022 S. Karger AG, Basel